Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 4cMET-dysregulated Advanced Solid Tumors 1Solid Tumours 1Prostatic Neoplasms 1Pain 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Fatigue 1Diverticulitis 1Confusion 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

Imatinib Mesylate 67Sunitinib 27nilotinib 14regorafenib 13ripretinib 10avapritinib 5Ipilimumab 5Dasatinib 5spartalizumab 4Laparoscopy 4CTLA-4 Antigen 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Bevacizumab 3trametinib 2tanespimycin 2ponatinib 2pembrolizumab 2masitinib 2famitinib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Stromal Tumors × Caffeine × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡